Blog Category

Press Releases

Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia

,

/

11 September 2023

Biophytis to Participate at the H.C. Wainwright 25 th Global Investment Conference in New York

,

/

4 September 2023

Biophytis announces next regulatory steps in Europe and the United States for its COVA project

,

/

16 August 2023

Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe

,

/

8 August 2023

Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19

,

/

20 July 2023

Biophytis Announces $3.8 Million Registered Direct Offering

,

/

19 July 2023

Biophytis and SEQENS sign a partnership to produce Sarconeos

,

/

18 July 2023

HALF-YEAR REPORT ON THE BIOPHYTIS LIQUIDITY CONTRACT

, , ,

/

11 July 2023

Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16 th SCWD International Congress

,

/

19 June 2023

Results of the annual general meeting on june 16, 2023

,

/

16 June 2023

Biophytis to participate at the BIO International Convention in Boston from the 5th to the 8th of June

,

/

5 June 2023

Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-19

,

/

26 May 2023